摘要 |
The invention relates to specific binding members, particularly antibodies a nd active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The bindin g members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild - type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplifie d by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ I D Nos: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.</SDOAB > |
申请人 |
LUDWIG INSTITUTE FOR CANCER RESEARCH |
发明人 |
SCOTT, ANDREW MARK;PANOUSIS, CON;NICE, EDOUARD COLLINS;JUNGBLUTH, ACHIM;JOHNS, TERRANCE GRANT;RENNER, CHRISTOPH;OLD, LLOYD J.;RITTER, GERD;BURGESS, ANTHONY WILKS;CAVENEE, WEBSTER K.;COLLINS, PETER;HUANG, HUEI-JEN;STOCKERT, ELISABETH |